Big pharmaceutical and logistics companies say draft good distribution practice (GDP) guidelines from the European Commission would "significantly increase the cost of medicinal product supply chains," according to a published report by Outsourcing Pharma.
The statement is attributed UPS, a worldwide shipper, that is concerned about the classification of any period when products are held at a site for longer than 24 hours as a regulated activity.
The report states a scientist at Merck Sharp & Dohme called the requirement "excessive and not realistic." A representative from Bristol-Myers is worried that carries will refuse to ship pharmaceutical products to do the demands of the draft GDP guidelines.
Read more:
Outsourcing Pharma: GDP Guidelines Would Increase EU Supply Chain Costs; Industry